Bryan Johnson has launched a US$1m-a-year longevity programme with just three places, offering access to the exact protocol he has followed for five years.

The programme, called “Immortals”, is offered by the former fintech entrepreneur, now a prominent and often controversial figure in longevity.

Johnson’s unconventional methods have included Botox injections in his genitals (Botox relaxes muscles) and transfusions of blood from his teenage son.

There is no evidence these will help him outlive others.

The “Immortals” package includes a dedicated concierge team, 24/7 access to the BryanAI health coach, extensive testing, continuous tracking of millions of biological data points and what Johnson calls the “best skin and hair protocols.

A lower-cost supported tier is available at US$60,000 per year.

Rivals also target the ultra-wealthy: Biograph’s premium membership costs US$15,000 per year, while Fountain Life’s “ultimate longevity programme” is priced at US$21,500 annually.

Despite the higher price, Johnson’s offer is built on exclusivity, with only three spots available.

Cognition Health and Cera have partnered to expand access to Alzheimer’s clinical trials across the UK.

The collaboration links Re:Cognition Health’s specialist brain health clinics and trial expertise with Cera’s 2.5 million monthly home care visits, creating new pathways to identify and support people earlier in their health journey.

By connecting home care with specialist research centres, the partners aim to offer more people the chance to join studies, giving access to advanced assessment and emerging treatments while contributing to future therapies.

Dr Ben Maruthappu MBE, chief executive and founder of Cera, said: “Many older adults are currently ‘invisible’ to the clinical trials research system because they cannot access traditional clinic-centric recruitment.

“By enabling responsible, consented identification and screening within the home, we can bridge the gap between the community and the clinic.

“We are offering the older generation a seat at the table of global drug discovery, ensuring that the path to a cure starts where they are most comfortable—in their own daily lives.”

Re:Cognition Health has contributed to the development of lecanemab (Leqembi) and donanemab (Kisunla) through international trials, introducing disease-modifying approaches that are reshaping early intervention in Alzheimer’s care.

Older adults remain under-represented in research. NIHR data indicate only about 15 per cent of trial participants are 75 or older, despite high multimorbidity in this group. Dementia trial recruitment in the UK also lags other disease areas.

Through this collaboration, individuals who have not yet accessed specialist memory services can be referred earlier for assessment and potential study participation, with access to new-generation therapies where appropriate.

Cera’s technology-enabled home healthcare model, with daily patient contact and consented data capture, allows timely referral of potential participants from familiar settings to Re:Cognition Health clinics.

Together, the organisations will support earlier and more equitable participation by leveraging Cera’s scale and real-time insights. Carers and nurses deliver visits roughly every second on average, enabling early identification of those who may benefit from memory assessment.

Dr Emer MacSweeney, chief executive and founder of Re:Cognition Health, said: “With one in three people expected to develop dementia in their lifetime, it is essential that we create more inclusive and accessible routes into research.

“This collaboration enables us to extend our reach beyond traditional clinic settings and ensure that people who may benefit from early assessment and research participation are supported to do so.

“Clinical trials offer individuals access to the most advanced diagnostics and emerging treatments, alongside expert medical oversight.

“By identifying people earlier and guiding them through every stage of their journey, we can help improve participants’ experience and potential outcomes, while accelerating the development of the next generation of Alzheimer’s therapies.”

Labcorp has launched what it describes as the first FDA-cleared blood test for Alzheimer’s disease assessment in primary care settings nationwide.

The Elecsys pTau-181 helps clinicians rule out the neurodegenerative disorder by identifying which symptomatic patients aged 55 and older are unlikely to have amyloid pathology, abnormal protein build-up in the brain associated with the disease.

Patients with negative results can be evaluated for other potential causes of cognitive decline, while patients with positive results can be referred for additional testing.

The diagnostic was developed by Roche Diagnostics and cleared by the US Food and Drug Administration in 2025.

Brian Caveney, chief medical and scientific officer at Labcorp, said: “Primary care clinicians are often the first point of contact for patients with concerns related to cognitive symptoms, yet Alzheimer’s testing has historically required a visit to a specialist.

“By making this first-of-its-kind blood test available nationwide, Labcorp is giving primary care clinicians a powerful tool to help patients get answers sooner and guide next steps with confidence.”

The Elecsys pTau-181 offers 97.9 per cent negative predictive value, a measure of how accurately it can rule out the condition in symptomatic patients, according to the company.

The diagnostic is performed via a simple blood draw, which can be completed in a doctor’s office or at any of Labcorp’s more than 2,200 patient service centres nationwide.

It provides an alternative to traditional approaches that require brain scans or lumbar punctures, procedures to collect spinal fluid, which can be costly, invasive or difficult to access.

The company says it can help reduce unnecessary referrals amid a national shortage of neurologists, supporting timely evaluation of other causes of cognitive decline.

An estimated 7.2 million Americans live with the disease.

Labcorp’s portfolio includes blood-based biomarker diagnostics for Alzheimer’s disease and other forms of dementia.